Clinical Trials Study

Study of rhIL-12 for treatment of complications after radiotherapy for tumor patients

Answer to reviewers file

Q1: The discussion section should be following the chronological order of their methodology and results. The pitfalls of their trial should also be expanded.

A1: The experiment reviewed the clinical research of rhuIL-12 for radiation therapy complication in tumor patients. Discussion section was written in the order of the preliminary research on IL-12, including the basic experiment and clinical trials. Previous experiments showed that IL-12 has important effect on immune function, which has the good research and development value. However, with the progress of the experiment, the side effects of IL-12 were found, including fever, gastrointestinal tract reaction, hemolytic anemia, etc, which were positively correlated with the dosage. RhuIL-12 is an immunoregulatory protein produced by gene engineering technology, which has similar biological activity to IL-12. With the merit of high efficiency and less usage, rhuIL-12 could be
applied in clinical treatment gradually. Over a two-year period, 200 advanced tumors patients were involved in the experiment. Over the course of the trial, some patients died or other reasons interrupted the experiment. Finally, the experimental data of 100 patients were written in articles. Certainly, we will expand the scale unceasingly.

Q2: There should be a summary of a clinical use of IL-12 as to its utility aside to its disadvantages the authors have pointed out. This is directly related to the novelty of the current findings with rhIL-12.

A2: The summary of a clinical use of IL-12 in discussion sections, recommended dosages was 150ng/kg.

Q3: The test was observed the patients who treated with radiotherapy once, but we know many patients needs more than one time, so I think maybe the research could go on and observing the patients who treated with repeated radiotherapy.

A3: In this experiment, the patients received a shot injection and accomplished the radiotherapy as planned.

Q4: Throughout the MS, there are many errors in gramma, wording, and vocabulary.

A4: The grammatical errors in the article have been corrected, however, in the email the reviewer pointed out that the wording: “The studies finally showed that the two cytokines were the same substance, known as IL-12”. The first cytokine mentioned is that one
promote in synergy of IL-2. Thus, it is contradictory to the previous sentences. A reader could totally lose its understanding if there is a wording error. Please make sure if you take IL2 as IL12, thanks for reviewing.

Correspondence to: Dr Yishan Wang, Center for Tumor Treatment, People's Liberation Army 107th Hospital, 7 Zhichu South Road, Yantai, Shandong 264003, P.R. China.
E-mail: wangyishan288@163.com,
Telephone: 0535-2933528
Fax: 0535-2933500